ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Human Papillomavirus Recombinant Vaccine nonavalent

Also written as “V503”, “9vHPV Vaccine” and “9vHPV vaccine”.

Its studies are mostly in Papillomavirus Infections · Condylomata Acuminata · Uterine Cervical Neoplasms · Papilloma · Dengue, led by 5 companies.

Drug pageHuman Papillomavirus Recombinant Vaccine nonavalent: every studyMany companies study it; this page follows only the 25 they lead. All 74 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jul 21, 200925 company-led studies, 10 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck207 open or runningphase 3since Jul 21, 2009Jul 21, 2009Jan 15, 2027phase 3 · NCT04199689
Shanghai Bovax Biotechnologyits history only21 open or runningphase 3since Jun 8, 2020Jun 8, 2020none ahead
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chairits history only11 open or runningearly phase 1since Apr 28, 2025Apr 28, 2025none ahead
Takedaits history only10 open or runningphase 3since Mar 16, 2020Mar 16, 2020none ahead
Xiamen Innovax Biotechits history only11 open or runningphase 4since Jun 16, 2026Jun 16, 2026Feb 28, 2027phase 4 · NCT07668271

Also a collaborator on its studies: Chongqing Bovax Biopharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jul 21, 2009.

  1. Nov 8, 2013Phase 3 study in Papillomavirus InfectionsNCT01984697 · 1,518 enrolled
  2. Apr 8, 2014Phase 3 study in Papillomavirus InfectionsNCT02114385 · 500 enrolled · Belgium, Germany, Netherlands
  3. May 16, 2017Phase 3 study in Uterine Cervical NeoplasmsNCT03158220 · 1,212 enrolled · Austria, Belgium, Finland and more
  4. May 23, 2018Phase 3 study in Papillomavirus InfectionsNCT03546842 · 201 enrolled · Vietnam
  5. Apr 3, 2019Phase 3 study in Papillomavirus InfectionsNCT03903562 · 1,990 enrolled · China
  6. Jun 21, 2019Phase 3 study in Papillomavirus InfectionsNCT03998254 · 6,000 enrolled · China
  7. Dec 12, 2019Phase 3 study in Papillomavirus InfectionsNCT04199689 · 6,033 enrolled · United States, Belgium, Brazil and more
  8. Nov 5, 2020Phase 3 study in Condylomata AcuminataNCT04635423 · 1,059 enrolled · Japan
  9. Jan 12, 2021Phase 3 study in Papillomavirus InfectionsNCT04708041 · 700 enrolled · United States, Colombia, Mexico and more
  10. Feb 23, 2021Phase 3 study in Papillomavirus InfectionsNCT04772534 · 314 enrolled · Japan
  11. Nov 10, 2021Phase 3 study in Papillomavirus InfectionsNCT05119855 · 165 enrolled · United States
  12. Mar 8, 20222 phase 3 studiesNCT05285826, NCT05314023
  13. Jun 28, 2022Phase 3 study in Papillomavirus InfectionsNCT05450705 · 1,500 enrolled · China
  14. Aug 21, 2026Phase 3 study in Papillomavirus InfectionsNCT07785843 · 930 planned · China

Ahead

  1. Jan 15, 2027Primary completion: phase 3 study in Papillomavirus InfectionsNCT04199689
  2. Dec 18, 2027Primary completion: phase 3 study in Papillomavirus InfectionsNCT07785843
  3. Mar 31, 2028Primary completion: phase 3 study in Papillomavirus InfectionsNCT03998254
  4. Feb 19, 2029Primary completion: phase 3 study in Condylomata AcuminataNCT05314023

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

Studies

All 20 Merck leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07785843Papillomavirus Infections · China3RecruitingDec 18, 2027930
NCT05450705Papillomavirus Infections · China3Active, not recruitingAug 3, 20291,500
NCT05314023Condylomata Acuminata · China3Active, not recruitingFeb 19, 20291,590
NCT05285826Papillomavirus Infections · China3Active, not recruitingMay 25, 20298,100
NCT05119855Papillomavirus Infections · United States3CompletedDec 12, 2023165
NCT04772534Papillomavirus Infections · Japan3CompletedApr 6, 2024314
NCT04708041Papillomavirus Infections · United States, Colombia, Mexico and more3Active, not recruitingOct 23, 2029700
NCT04635423Condylomata Acuminata · Japan3CompletedDec 31, 20231,059
NCT04199689Papillomavirus Infections · United States, Belgium, Brazil and more3Active, not recruitingJan 15, 20276,033
NCT03998254Papillomavirus Infections · China3Active, not recruitingMar 31, 20286,000
NCT03903562Papillomavirus Infections · China3CompletedFeb 28, 20251,990
NCT03546842Papillomavirus Infections · Vietnam3CompletedJan 29, 2019201
NCT03158220Uterine Cervical Neoplasms · Austria, Belgium, Finland and more3CompletedNov 19, 20181,212
NCT02114385Papillomavirus Infections · Belgium, Germany, Netherlands3CompletedApr 22, 2015500
NCT01984697Papillomavirus Infections3CompletedJun 19, 20151,518
NCT01651949Condylomata Acuminata3CompletedAug 4, 20142,520
NCT01304498Human Papillomavirus3CompletedDec 20, 2011600
NCT01254643Papillomavirus Infections3CompletedAug 10, 2013100
NCT01047345Uterine Cervical Neoplasms3CompletedJun 10, 2011924
NCT00943722Uterine Cervical Neoplasms3CompletedApr 30, 20113,074

How it is read

Names in the registry

  • “V503”, 10 entries
  • “9vHPV Vaccine”, 5 entries
  • “9vHPV vaccine”, 5 entries
  • “9-valent HPV vaccine (Cecolin 9)”, 1 entry
  • “9vHPV Vaccine plus BCG Vaccine Mix for percutaneous use”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.